Publications by authors named "Harrah Chiang"

Claim this Profile
T
T-Cell Lymphoproliferative Disorders Following Allogeneic Bone Marrow Transplant: A Report of Two Cases and a Literature Review.
Nicholas Prabhakar, Harrah Chiang, Irma Munoz Verdugo, Ari Hakimian, Shams Bufalino

Cureus· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Report of Cholangiocarcinoma With Transheterozygous BRCA1 and BRCA2 Co-mutation.
Nicholas Prabhakar, Harrah Chiang, Edward Nabrinsky, John Eklund

Cureus· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simulating Early Clinical Experiences With Surgical Procedures in the Anatomy Laboratory.
Tayler Gant, Harrah Chiang, Benjamin D Harman, David S Axford, Paul Brisson

Cureus· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of the Clinical Development Candidate , a Covalent KRAS Inhibitor for the Treatment of Cancer.
Jay B Fell, John P Fischer, Brian R Baer, James F Blake, Karyn Bouhana, Harrah Chiang

J Med Chem· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.
Jay B Fell, John P Fischer, Brian R Baer, Joshua Ballard, James F Blake, Harrah Chiang

ACS Med Chem Lett· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
David Briere, Niranjan Sudhakar, David M Woods, Jill Hallin, Lars D Engstrom, Harrah Chiang

Cancer Immunol Immunother· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
Lars D Engstrom, Ruth Aranda, Matthew Lee, Elizabeth A Tovar, Curt J Essenburg, Harrah Chiang

Clin Cancer Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis